Special Treatment Certificate Issued for Importation of E. coli O157 Vaccine into the United Kingdom

Special Treatment Certificate Issued for Importation of E. coli O157 Vaccine into the United Kingdom PR Newswire BELLEVILLE, Canada, August 7, 2012 BELLEVILLE, Canada, August 7, 2012 /PRNewswire/ -- Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that the Veterinary Medicines Directorate (VMD) of the Department for the Environment, Food and Rural Affairs in United Kingdom has approved the importation of the Company's cattle vaccine against E. coli O157 for use under the conditions of a Special Treatment Certificate (STC). Dr. Chris Low, Director of One Health at the Royal (Dick) School of Veterinary Studies, University of Edinburgh, has been working with public health agencies in the UK, and with veterinary surgeons and various parts of the agricultural industry, to reduce the risk of E. coli O157 exposure. "Farming and livestock agriculture are vital to feeding a growing global population," said Dr. Low, "but One Health focusses on the disease risks and challenges brought about by the interactions between animals, humans and the environment, and I am very pleased that here we have available in the UK a new approach to control of this infection." STCs are issued to veterinary surgeons when an appropriate remedy for an animal disease is not available in the UK, but can be accessed from another country. In this precedent-setting case, the VMD recognised that, although E.